TNFSF11 and osteoporosis: To avoid any potential side effects of the systemic administration of RANKL, such as osteoporosis, possible strategies would be to deliver directly this molecule intrathymically in patients after cytoablative conditioning or to combine RANKL with bisphosphonates to prevent bone resorption (Tomimori et al, 2009).